semaglutide 7.2 mg clinical trial Once-Weekly in Adults with Overweight or Obesity Semaglutide 7.2 mg Displays 20.7%

If anti-obesity medications were to be approved for OSA treatment, clinicians would need to be aware that its vital to primarily address proper nutrition, tolerable physical activity, and identification of weight-modifying behaviors while using anti-obesity medications as complementary tools to treat obesity, Dr

Slowed gastric emptying means slowed intestinal motility overall

Take it at the same time every day to build a consistent routine

Vlachou, M., Siamidi, A., Dedeloudi, A., Konstantinidou, S

Of particular concern are gastrointestinal complications like gastroparesis (stomach paralysis), which can cause severe nausea, vomiting, and difficulty digesting food

Continue follow-up visits as recommended by your clinician, typically monthly during titration and every 1-3 months once stable